TLRK is one of a few small molecule discovery companies that works on therapeutic agents that could meet the medical needs of people represented by large markets. They have top notch scientists (I particularly think highly of some of their chemists, they have innovative biology, they have a reasonable balance sheet, they have solid collaborations, particularly with JT, and again, they can discover the product and at least do part of the clinical studies necessary for approval.
Don't get me wrong, contrary to what some may think this is a really tough business, but once successful, the profit margins can be outstanding. Moreover, the stock has been hammered with a capital H. I also like the fact that Goeddel and Saxton are buying. Not that these impressive scientists are guaranteed to be correct in their timing, but myself as a scientist I believe that they are confident about the future and I like their patent estate as partial support for this comment. This is NOT a solicitation for others to buy, just my own feeling.
As to the timing, who the H knows. This is a partial position for me at this time. I really like the extremely beat up small molecule discovery biotechs in this environment, and am starting to pick up a basket of several.
(Peter, I know I did not answer the question you asked me about a month ago about some names I liked in this environment, but since I said here that I in part am focusing on small molecule discovery and development biotechs, several of the usual suspects may come to mind.)
BJ |
